Evidence map›Paper›PMID 42121859›Full record

ReviewCells2026

Thoughts and Therapies: Melanoma Brain Metastases.

Chaitanya Sanghadia, Milena Nicosia, Caroline Castelino, Neil Talwar, Safwan Kazmi, Jason Ramirez, Vikas Prabhakar, Matthew Lobato, Albert Nguyen, Tomasz Czerkas and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chaitanya SanghadiaArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.ORCID 0009-0008-3719-1847
Milena NicosiaArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Caroline CastelinoArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Neil TalwarArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Safwan KazmiArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Jason RamirezArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Vikas PrabhakarArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Matthew LobatoArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Albert NguyenArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.ORCID 0009-0007-8854-6583
Tomasz CzerkasArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Zachary RundellArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Shaan BhullarCollege of Medicine Phoenix, University of Arizona, Phoenix, AZ 85004, USA.ORCID 0009-0005-4558-7807
Hunter HutchinsonDepartment of Neurosurgery, University of Florida, Gainesville, FL 32611, USA.ORCID 0009-0005-3202-3949
Brandon Lucke-WoldDepartment of Neurosurgery, University of Florida, Gainesville, FL 32611, USA.ORCID 0000-0001-6577-4080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastases are the third most common metastatic site in melanoma patients, with 40% of melanoma patients developing melanoma brain metastasis (MBM). Symptomology of MBM ranges from headaches, neurological deficits, cognitive changes, and seizures, resulting from MBM embedding in areas of highest blood flow following the breakdown of the blood-brain barrier (BBB) via genetic, cytokine, and molecular processes. The BBB is highly restrictive, making MBM difficult to treat. Challenges in MBM treatment are evident in adverse therapeutic effects, such as neurocognitive decline with whole-brain radiation therapy (WBRT), increased risk of radiation necrosis with stereotactic radiosurgery (SRS), and reduced penetration into the brain, which can lead to drug resistance with prolonged use of

Indexed as

Brain NeoplasmsMelanomaAnimalsBlood-Brain BarrierHumansImmunotherapybrainMAPKmelanomametastasisradiotherapytargeted therapy

Identifiers

PMID42121859
PMCPMC13162886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.